Profile data is unavailable for this security.
About the company
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
- Revenue in USD (TTM)11.76m
- Net income in USD-200.07m
- Incorporated2018
- Employees255.00
- LocationVerve Therapeutics Inc201 Brookline Avenue, Suite 601BOSTON 02215United StatesUSA
- Phone+1 (978) 501-3026
- Fax+1 (302) 655-5049
- Websitehttps://www.vervetx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Korro Bio Inc | 0.00 | -81.17m | 535.71m | 101.00 | -- | 3.15 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| OmniAB Inc | 34.16m | -50.62m | 537.61m | 106.00 | -- | 1.71 | -- | 15.74 | -0.4986 | -0.4986 | 0.3292 | 2.69 | 0.0858 | -- | 2.00 | 322,301.90 | -12.71 | -- | -13.55 | -- | -- | -- | -148.16 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Novavax Inc | 983.71m | -545.06m | 544.42m | 1.54k | -- | -- | -- | 0.5534 | -5.53 | -5.53 | 9.42 | -5.14 | 0.485 | 8.76 | 5.18 | 637,527.60 | -26.88 | -46.06 | -- | -269.57 | 65.10 | -- | -55.41 | -75.94 | 0.6741 | -38.31 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Nkarta Inc | 0.00 | -117.50m | 546.79m | 150.00 | -- | 1.40 | -- | -- | -2.40 | -2.40 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -27.59 | -32.39 | -29.14 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Exscientia PLC (ADR) | 24.97m | -181.51m | 549.88m | 483.00 | -- | 1.24 | -- | 22.02 | -1.44 | -1.44 | 0.1986 | 3.52 | 0.0346 | 1,096.08 | 9.86 | 51,694.18 | -25.16 | -- | -29.09 | -- | -36.47 | -- | -726.94 | -- | 6.22 | -- | 0.0505 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| ProKidney Corp | 0.00 | -35.47m | 550.42m | 163.00 | -- | -- | -- | -- | -0.5683 | -0.5683 | 0.00 | -18.43 | 0.00 | -- | -- | 0.00 | -28.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| Prime Medicine Inc | 0.00 | -198.13m | 550.52m | 234.00 | -- | 3.36 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -96.66m | 553.56m | 74.00 | -- | 2.14 | -- | -- | -2.16 | -2.16 | 0.00 | 4.62 | 0.00 | -- | -- | 0.00 | -39.24 | -30.06 | -42.54 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 682.00k | -201.59m | 554.81m | 452.00 | -- | -- | -- | 813.50 | -3.89 | -3.89 | 0.0133 | -1.26 | 0.0024 | -- | -- | 1,508.85 | -69.68 | -83.26 | -78.50 | -93.77 | 75.51 | -- | -29,558.94 | -135,982.00 | 10.22 | -4.91 | 1.20 | -- | -- | -- | -1.96 | -- | -- | -- |
| Verve Therapeutics Inc | 11.76m | -200.07m | 556.90m | 255.00 | -- | 0.9106 | -- | 47.36 | -3.13 | -3.13 | 0.1832 | 7.31 | 0.0164 | -- | 3.40 | 46,109.80 | -27.94 | -- | -29.43 | -- | -- | -- | -1,701.55 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Absci Corp | 5.72m | -110.57m | 560.54m | 155.00 | -- | 2.63 | -- | 98.03 | -1.20 | -1.20 | 0.0621 | 1.89 | 0.0212 | -- | 3.06 | 36,890.32 | -41.08 | -- | -46.22 | -- | -- | -- | -1,933.65 | -- | -- | -93.25 | 0.0467 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Fate Therapeutics Inc | 63.53m | -160.93m | 570.39m | 181.00 | -- | 1.35 | -- | 8.98 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -118.46m | 575.44m | 186.00 | -- | 2.31 | -- | -- | -2.39 | -2.39 | 0.00 | 3.64 | 0.00 | -- | -- | 0.00 | -50.06 | -40.85 | -54.08 | -44.48 | -- | -- | -- | -- | -- | -- | 0.113 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Dec 2023 | 7.03m | 8.94% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 5.40m | 6.87% |
| Federated Global Investment Management Corp.as of 31 Dec 2023 | 3.98m | 5.07% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.95m | 5.03% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.87m | 4.92% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 3.17m | 4.04% |
| Casdin Capital LLCas of 31 Dec 2023 | 3.01m | 3.83% |
| Nikko Asset Management Americas, Inc.as of 31 Dec 2023 | 2.40m | 3.05% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.15m | 2.74% |
| Redmile Group LLCas of 31 Dec 2023 | 1.72m | 2.19% |
